NEWS

Abbvie receives FDA orphan drug designation for investigational medicine Veliparib

Monday, Nov 07, 2016

Abbvie Inc Currently investigating efficacy, safety of Veliparib in combination with chemotherapy or radiation for treatment of advanced Squamous Nsclc.

Abbvie receives FDA orphan drug designation for investigational medicine Veliparib for the treatment of advanced squamous non-small cell lung cancer.

 

Source : reuters.com